Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.
Luina Bio, an Australian biopharmaceutical CDMO, has been acquired by a biotech investor and a private equity group, namely Dr Glenn Haifer and Ampersand Capital Partners.
Contract development and manufacturing organization (CDMO), Recipharm, is now better placed to serve the advanced therapy medicinal products (ATMPs) market through two deals announced today.